Challenges in the implementation of trastuzumab biosimilars. Issue 10 (November 2015)

• Record Type: Journal Article
• Authors: Pivot, Xavier; Aulagner, Gilles; Blay, Jean Yves; Fumoleau, Pierre; Kaliski, Alexandre; Sarkozy, François; Limat, Samuel
• Is Part Of: Anti-cancer drugs. Volume 26:Issue 10(2015)
• Publication Date: 2015-11
• Subjects: Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000287
• Languages: English
• ISSNs: 0959-4973

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>Trastuzumab has transformed the treatment of HER2-positive breast cancer. Because of impending European patent expiry in 2017, numerous trastuzumab biosimilars are currently undergoing comparability exercises for marketing authorization. Although biosimilar products have been approved in Europe since 2006, many obstacles are expected for trastuzumab, resulting from its nature as a monoclonal antibody, its impact on overall survival, and its extensive biochemical complexities. Unsolved questions need to be addressed for the evaluation of biosimilars' activity in terms of appropriate clinical endpoint definitions for such anticancer drugs, specific assessment pathways and comparative testing of biosimilars, untested ensuing <italic>de facto</italic> combination of trastuzumab biosimilars with cytotoxics, and immunogenicity monitoring among immunocompromised patients. In such a context of uncertainties, the recent approval by the French parliament of biosimilar substitution, which would allow dispensing trastuzumab biosimilars in place of the originator, should interrogate the oncological community. A think tank of experts was created to delineate specificities and challenges stemming from trastuzumab biosimilars.</p> </sec> </abstract>